Alerta

METHODS OF DIAGNOSING AND TREATING MOOD AND PSYCHOTIC DISORDERS USING LYMPHOCYTE BIOMARKERS

Absstract of: AU2025231883A1

Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection/analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.

METHODS AND COMPOSITIONS FOR MEASURING AND MANAGING OXIDATIVE STRESS LEVELS

Absstract of: AU2025231935A1

Provided herein are methods for providing personalized antioxidant supplement blend for an individual subject based on the levels of antioxidant biomarkers, prooxidant biomarkers, and genetic statuses. The antioxidant supplement blend includes suggestions for one or more of diet, supplements, and/or life style changes for the individual.

DETECTION OF BIOMARKERS ON VESICLES FOR THE DIAGNOSIS AND PROGNOSIS OF DISEASES AND DISORDERS

Absstract of: US20260318925A1

Methods are disclosed that comprise providing a biological sample comprising extracellular vesicles, wherein the biological sample further comprises at least one extracellular vesicle biomarker and at least one cytosolic protein, cytokine, or secreted disease biomarker; contacting a solid support comprising capture agents associated therewith with the biological sample under conditions wherein the capture agents selectively bind to the at least one extracellular biomarker on the vesicles, thereby capturing said vesicles having the at least one extracellular vesicle biomarker on the solid support; separating the solid support from the biological sample; detecting a level of the at least one cytosolic protein, cytokine or secreted disease biomarker on the vesicles captured on the solid support using a detection agent that selectively binds to the at least one cytosolic protein, cytokine or secreted disease biomarker, wherein the vesicles are not lysed or permeabilized; detecting a level of the at least one extracellular vesicle biomarker on the vesicles; and determining a level of risk or presence of a neurological disorder or neurodegenerative disease based on the level of the at least one cytosolic protein, cytokine, or secreted disease biomarker in relation to the level of the at least one extracellular vesicle biomarker.

DETERMINING A HEALTH-RELATED CONDITION BY SELECTIVELY PERFORMING NUCLEIC ACID SEQUENCING IN RESPONSE TO A SCREENING TEST

Absstract of: US20260321424A1

Techniques for identifying a health-related condition based on a protein-based analysis, and optionally based on a nucleic acid sequencing-based analysis are described. In an example method, protein data of a sample obtained from the subject is identified. The sequence read data is indicative of proteins in the sample. The example method further comprises determining a protein score based on the protein data, and determining, based on the protein score, whether to determine a genomic score indicative of sequences of nucleic acid molecules in the sample. In the example method, input features are generated based on the protein score and/or the genomic score and classifying, using a classifier, the health-related condition of the subject based on the input features.

AGENTS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA

Absstract of: WO2026217989A1

Provided herein are methods of treating a subject having benign prostatic hyperplasia that include, for example, identifying a subject having a white blood cell that has an elevated level of methylation of SRD5A2 as compared to a reference level; and administering to the identified subject a first therapy such as a combination therapy comprising a therapeutically effective amount of a 5-alpha reductase inhibitor and a stroma-niched signaling therapeutic.

SALIVARY ENDOTOXIN DETECTION USING COMBINED MONO/POLYCLONAL ANTIBODY-BASED SANDWICH-TYPE LATERAL FLOW IMMUNOASSAY DEVICE

Absstract of: US20260318911A1

0000 A lateral flow assay device for detecting the presence of, or quantifying an amount or concentration of, analyte in a sample. The device includes (1) a conjugate region including a binding reagent coupled to a signal-generating particle, wherein the binding reagent comprises a first antibody configured to bind lipopolysaccharide, and wherein the binding reagent is mobile relative to the device, and (2) an analytical membrane in fluid communication with the conjugate region, the analytical membrane comprising a test region and a control region. The test region includes an immobilized capture reagent configured to capture a complex including the analyte and the binding reagent, wherein the immobilized capture reagent is a second antibody. The control region includes a control component configured to capture the binding reagent coupled to the signal-generating particle.

PREDICTION OF CAR NEUROTOXICITY USING NETWORK BIOSIGNATURES

Absstract of: WO2026218003A2

Provided are methods and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as severe neurotoxicity or severe CRS. The methods generally involve determining a biosignature comprising of a differential modulation of one or more protein-interactions in a CAR-T cell to be administered relative to a reference standard. In some embodiments, the methods further involve administering an agent or therapy for treating, ameliorating, preventing, delaying and/or attenuating the development of the toxicity, such as neurotoxicity or CRS, such as severe neurotoxicity or severe CRS.

DETECTING AND MONITORING CHEMICAL AND BIOLOGICAL ANALYTES IN THE NASAL CAVITY USING MACHINE LEARNING-BASED ELECTROCHEMICAL PROCESSES

Absstract of: WO2026217919A1

Various examples are provided related to monitoring at least one chemical analyte, biological analyte, or combinations thereof in the nasal cavity. In one example, a process includes receiving an output signal from an electrochemical sensor, applying a trained machine learning model or algorithm to the output signal to detect a presence of at least one analyte in the nasal cavity, and determining, in response to the detected presence, an identity or amount of the analyte. In another example, a process includes receiving an output signal from an electrode implanted in the nasal cavity, applying a trained machine learning model or algorithm to the output signal to determine a neurochemical analyte. The information can be displayed to indicate a corresponding neurochemical level in the nasal cavity of a subject.

PERSONALIZED SYNTHETIC BIOMARKER PANELS

Absstract of: US20260317833A1

Methods and systems for detecting disease using personalized synthetic biomarkers. Subject-specific molecular data, including one or more of genomic, epigenomic, transcriptomic, proteomic, or metabolomic data, are analyzed to identify disease-associated biological activities. Based on these activities, a set of synthetic biomarkers is designed for the subject, wherein each biomarker is configured to generate a detectable signal in response to a target biological process. The synthetic biomarkers are administered to the subject or contacted with a biological sample, and resulting signals are detected using analytical assays. Detection of the signals enables identification, monitoring, or assessment of disease presence, progression, or recurrence. In certain embodiments, the methods are applied to cancer, including minimal residual disease (MRD) detection, and may incorporate longitudinal monitoring and adaptive updating of biomarker panels based on changes in subject-specific molecular profiles.

METHOD TO DETERMINE THE EFFICACY OF A NEURODEGENERATIVE DISEASE TREATMENT

Absstract of: US20260318926A1

The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.

Systems, Compositions, and Methods to Control the Integrated Stress Response

Absstract of: US20260317734A1

0000 Many embodiments are directed to systems, compositions, and methods to control the ISR. Numerous embodiments utilize optogenetic control to control the ISR. Optogenetic control can be provided by an engineered ISR kinase that can dynamically stimulate the ISR pathway. Using optogenetic control, many embodiments enable the selective activation of a single kinase of the ISR pathway without inducing real molecular damage, greatly reducing the combinatorial complexity of the signals that are turned on by real stressors. By changing the intensity of light stimulation, various embodiments can tune the fraction of optogenetic proteins in the activated state, thereby precisely altering the perceived intensity. Additionally, precisely defined input dynamics can be delivered by toggling lights between on and off positions. Many embodiments are scalable and/or capable of high-throughput delivery, allowing for precise dissections of the ISR pathway.

ANTI-IL1RAP ANTIBODIES

Absstract of: US20260317434A1

The present invention relates to antibodies or antigen-binding fragments thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibodies, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibodies or antigen-binding fragments. Further, it relates to a composition comprising said antibodies or antigen-binding fragments, said polynucleotide, said vector and/or said host cell. Further, it relates to said antibodies or antigen-binding fragments, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1α, IL-1β, IL-33, IL-36α, IL-36β and/or IL-36γ signaling, optionally wherein the disease or disorder is associated with cells expressing IL1RAP.

Method of nociceptor differentiation of human embryonic stem cells and uses thereof

Absstract of: AU2026237984A1

The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling. ep e p

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

Absstract of: US20260317373A1

The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.

METHOD FOR QUANTIFYING ERGOTHIONEINE

Absstract of: WO2026216120A1

The present disclosure can provide a simple and accurate method for quantifying ergothioneine in a sample containing globin protein. The present disclosure provides a method for quantifying ergothioneine in a collected sample, the method including: (A) a step for heating the sample; (B) a step for mixing the heated sample with trichloroacetic acid; and (C) a step for subjecting the sample obtained in step (B) to a quantification operation.

BRAIN-TARGETING PEPTIDE, TRANSPORT CARRIER, AND METHOD FOR SCREENING PEPTIDE BINDING TO TARGET CELL

Absstract of: EP4821941A1

The present invention provides a cerebrum-targeting peptide including an amino acid sequence represented by SEQ ID NO: 1, and a method for screening a peptide that binds to a target cell in a non-human organism, comprising contacting a peptide library consisting of 7-amino acid peptides with a target cell to recover a group of peptides that bind to the target cell to obtain a peptide population that binds to the target cell, and selecting, from the peptide population, a peptide consisting of an amino acid sequence that is identical to a portion of a protein expressed in the non-human organism and that is also identical to a portion of a protein constituting a virus, as a peptide that binds to the target cell.

MAGNETIC FORMULATIONS FOR BIOMARKER SAMPLING AND ENHANCED DRUG DELIVERY

Absstract of: WO2025118073A1

The present disclosure describes formulations, methods, and devices for biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.

認知障害の処置方法

Absstract of: WO2025064229A1

The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.

HSP70 PROTEIN LEVELS IN PBMC SAMPLES AS BIOMARKER FOR DISEASE

Absstract of: EP4822355A2

0001 Disclosed herein are methods based on the identification of reduced Hsp70 levels in PBMC samples serving as a biomarker for diseases presenting with a reduced level of Hsp70, such as lysosomal storage diseases, neurodegenerative diseases and muscular diseases.

細胞透過剤及びその使用

Absstract of: WO2025059487A2

The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).

アミロイド疾患の診断方法

Absstract of: MX2026002775A

The present disclosure relates in some aspects to methods and compositions for detecting an amyloid-related disease in an individual.

細胞透過剤及びその使用

Absstract of: MX2026003211A

The present disclosure provides cell-penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human TDP-43 and methods of using these cell-penetrating agents to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).

用于半定量检测生物样本中路易折叠型α-突触核蛋白病理种子负荷的方法、试剂盒及其应用

Absstract of: CN122882748A

本发明属于生物医药技术领域，公开了一种用于半定量检测生物样本中路易折叠型α‑突触核蛋白病理种子负荷的方法、试剂盒及其应用。本发明首次将α‑突触核蛋白种子扩增技术从定性检测升级为半定量检测：首先进行阳性样本初筛，然后对初筛阳性样本进行基质匹配的系列稀释，结合长时程种子扩增反应，统计所有稀释度复孔的阳性总数，获得路易折叠病理评分。LFP评分与帕金森病患者的Hoehn&Yahr分期、MDS‑UPDRS III运动评分呈正相关，与MoCA认知评分呈负相关，可用于疾病辅助诊断、严重程度辅助评估、进展监测及药效辅助评价。该方法亦可用于检测阿尔茨海默病患者样本中的α‑突触核蛋白种子，为共病理评估提供参考。

基于PROTAC蛋白靶向降解技术的薯蓣皂素类化合物靶点鉴定方法及PROTAC化合物

Absstract of: CN122878374A

0001 本发明公开了基于PROTAC蛋白靶向降解技术的薯蓣皂素类化合物靶点鉴定方法及PROTAC化合物。本发明以薯蓣皂苷元为靶蛋白配体合成双功能PROTAC分子；通过细胞毒性筛选确定毒性最小的探针，经差异蛋白质组学分析、Western blot、分子对接及CETSA验证确证YTHDF2为作用靶标；通过AD细胞模型验证了薯蓣皂苷通过YTHDF2发挥抗氧化和缓解突突触损伤的作用机制。还提供能够诱导YTHDF2降解的薯蓣皂苷元类PROTAC化合物及其在制备治疗神经退行性疾病药物中的用途。

一种基于编码微球的弓形虫IgG抗体多指标联检方法

Nº publicación: CN122882751A 09/10/2026

Applicant:

上海市重大传染病和生物安全研究院

Absstract of: CN122882751A

本发明公开了一种基于编码微球的弓形虫IgG抗体多指标联检方法。筛选三种低吸附编码微球，分别偶联弓形虫特异性抗原SAG1、MIC3和CST1；优化偶联缓冲液为MEST pH 5.0，抗原标记量降低50%，采用1%BSA+CE210+CE510封闭。样本添加量为5μL，以TBST为清洗液，添加0.2 mg/mL阻断剂和0.01 mg/mL兔抗人IgG‑PE二抗，样本孵育与二抗孵育各15分钟即可完成检测。以健康人群检测结果的均值加3倍标准差作为阳性判断阈值，对弓形虫IgG阳性待测样本进行检测。结果显示，SAG1、MIC3、CST1三个单项抗原的阳性检出率分别为13.56%、16.95%和13.56%，而三联检的阳性检出率提升至32.20%，显著高于任一单项检测。本发明实现了快速、低成本、高灵敏度的弓形虫IgG抗体多指标联检，解决了单一抗原检出率不足的问题。